PRLD
Income statement / Annual
Last year (2023), Prelude Therapeutics Incorporated's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Prelude Therapeutics Incorporated's net income was -$121.83 M.
See Prelude Therapeutics Incorporated’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.17 M |
$3.04 M |
$2.24 M |
$542,000.00 |
$382,000.00 |
$149,000.00 |
| Gross Profit |
-$1.17 M |
-$3.04 M |
-$2.24 M |
-$542,000.00 |
-$382,000.00 |
-$149,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$103.39 M
|
$92.89 M
|
$86.78 M
|
$48.18 M
|
$24.28 M
|
$12.62 M
|
| General & Administrative
Expenses |
$28.88 M
|
$30.65 M
|
$26.96 M
|
$10.59 M
|
$3.83 M
|
$2.35 M
|
| Selling & Marketing
Expenses |
-$1.17 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$28.88 M
|
$30.65 M
|
$26.96 M
|
$10.59 M
|
$3.83 M
|
$2.35 M
|
| Other Expenses |
$0.00 |
$8.10 M |
$2.04 M |
$1.83 M |
$539,000.00 |
$295,000.00 |
| Operating Expenses |
$132.28 M |
$123.54 M |
$113.74 M |
$58.76 M |
$28.11 M |
$14.98 M |
| Cost And Expenses |
$132.28 M |
$123.54 M |
$113.74 M |
$58.76 M |
$28.11 M |
$14.98 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$1.32 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.17 M
|
$3.04 M
|
$2.24 M
|
$542,000.00
|
$382,000.00
|
$149,000.00
|
| EBITDA |
-$131.11 M
|
-$123.54 M
|
-$113.74 M
|
-$58.22 M
|
-$27.73 M
|
-$14.83 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$10.45 M
|
$8.10 M
|
$2.04 M
|
$1.83 M
|
$539,000.00
|
$295,000.00
|
| Income Before Tax |
-$121.83 M |
-$115.44 M |
-$111.69 M |
-$56.93 M |
-$27.57 M |
-$14.68 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1.00 |
-$8.10 M |
-$915,000.00 |
$335,703.00 |
$210,140.00 |
$295,000.00 |
| Net Income |
-$121.83 M |
-$107.34 M |
-$110.78 M |
-$56.93 M |
-$27.57 M |
-$14.68 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.02 |
-2.27 |
-2.33 |
-1.3 |
-0.85 |
-0.46 |
| EPS Diluted |
-2.02 |
-2.27 |
-2.33 |
-1.3 |
-0.85 |
-0.46 |
| Weighted Average Shares
Out |
$60.36 M
|
$47.37 M
|
$47.60 M
|
$43.71 M
|
$32.40 M
|
$32.11 M
|
| Weighted Average Shares
Out Diluted |
$60.36 M
|
$47.37 M
|
$47.60 M
|
$43.71 M
|
$32.40 M
|
$32.11 M
|
| Link |
|
|
|
|
|
|
